Patent application number | Description | Published |
20130017249 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY - Here described are compounds consisting of the structure | 01-17-2013 |
20130022665 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 01-24-2013 |
20130071467 | RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis. | 03-21-2013 |
20130071478 | RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH | 03-21-2013 |
20130115274 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY - What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water. The final charge ratio of drug:lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm. | 05-09-2013 |
20130164400 | SINGLE USE SYSTEM FOR STERILELY PRODUCING LIPID-NUCLEIC ACID PARTICLES - What is described is a process of forming lipid-nucleic acid nanoparticles simply and reproducibly under aseptic conditions comprising single use components. | 06-27-2013 |
20130171127 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE - The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue. | 07-04-2013 |
20130171240 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS - Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells. | 07-04-2013 |
20130210744 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer. | 08-15-2013 |
20130330401 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes. | 12-12-2013 |
20140294934 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 10-02-2014 |
20140356413 | RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis. | 12-04-2014 |